BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30932408)

  • 1. Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia.
    Langabeer SE; Haslam K; Crampe M; MacDonagh B; McHugh J
    Exp Oncol; 2019 Mar; 41(1):82-83. PubMed ID: 30932408
    [No Abstract]   [Full Text] [Related]  

  • 2. Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
    Kantarjian H; Branford S; Breccia M; Cortes J; Haddad FG; Hochhaus A; Hughes T; Issa GC; Jabbour E; Nicolini FE; Sasaki K; Xavier-Mahon F
    Leukemia; 2024 May; 38(5):947-950. PubMed ID: 38531949
    [No Abstract]   [Full Text] [Related]  

  • 3. Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India.
    Kuila N; Dash N; Sahoo DP; Pattnayak NC; Biswas G; Chakraborty S
    Leuk Lymphoma; 2009 Apr; 50(4):663-6. PubMed ID: 19373669
    [No Abstract]   [Full Text] [Related]  

  • 4. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
    Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
    Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.
    Patel AB; O'Hare T; Deininger MW
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):589-612. PubMed ID: 28673390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
    Gniot M; Wasilewska EM; Lewandowski K
    Int J Lab Hematol; 2012 Dec; 34(6):e3-6. PubMed ID: 25998099
    [No Abstract]   [Full Text] [Related]  

  • 7. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
    Elnair R; Galal A
    BMC Cancer; 2018 Nov; 18(1):1097. PubMed ID: 30419862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
    Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
    Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors.
    Shojaei M; Rezvani H; Azarkeivan A; Poopak B
    Lab Med; 2021 Mar; 52(2):158-167. PubMed ID: 32821940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
    Oyekunle AA; Castagnetti F; Gugliotta G; Soverini S; Baccarani M; Rosti G
    Leuk Res; 2011 Jul; 35(7):e118-20. PubMed ID: 21489624
    [No Abstract]   [Full Text] [Related]  

  • 12. Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.
    Kamasani S; Akula S; Sivan SK; Manga V; Duyster J; Vudem DR; Kancha RK
    Tumour Biol; 2017 May; 39(5):1010428317701643. PubMed ID: 28475010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: a perspective of the SEPT9-ABL1 fusion protein.
    Hu T; Ciccarelli BT
    Leuk Res; 2014 Dec; 38(12):1399-400. PubMed ID: 25449686
    [No Abstract]   [Full Text] [Related]  

  • 14. Prolonged treatment-free remission in chronic myeloid leukemia patients with previous
    Claudiani S; Apperley JF; Khan A; Khorashad J; Milojkovic D
    Haematologica; 2020 May; 105(5):e225-e227. PubMed ID: 31537692
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.
    Franke GN; Maier J; Wildenberger K; Cross M; Giles FJ; Müller MC; Hochhaus A; Niederwieser D; Lange T
    J Mol Diagn; 2020 Jan; 22(1):81-89. PubMed ID: 31669230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variant isoforms of BCR-ABL1 in chronic myelogenous leukemia reflect alternative splicing of ABL1 in normal tissue - letter.
    Khorashad JS; Milojkovic D; Reid AG
    Mol Cancer Ther; 2010 Jul; 9(7):2152. PubMed ID: 20571070
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chronic myelogenous leukemia: diagnosis and treatment].
    Demeter J; Poros A; Bödör C; Horváth L; Masszi T
    Orv Hetil; 2016 Sep; 157(37):1459-68. PubMed ID: 27615196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roots of clinical resistance to STI-571 cancer therapy.
    Barthe C; Cony-Makhoul P; Melo JV; Mahon JR
    Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel
    Malik S; Hassan S; Eşkazan AE
    Expert Rev Hematol; 2021 Nov; 14(11):975-978. PubMed ID: 34608829
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia.
    Qin YZ; Huang XJ
    Methods Mol Biol; 2016; 1465():1-15. PubMed ID: 27581134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.